Others to follow Enbrel biosimilar launch in Australia, Merck & Co says
US pharma giant Merck & Co (NYSE: MRK) has pledged to follow up the launch of a biosimilar etanercept in Australia with more copycat biologics, promising to spare the country’s Pharmaceutical Benefits Scheme (PBS) from paying the full price of the reference products.
The original version of etanercept, which is indicated for rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis, is sold by US biotech major Amgen (Nasdaq: AMGN) under the name Enbrel, while Merck has called its biosimilar Brenzys.
"This is an important milestone given that it represents real progress in our efforts to offer Australian patients and healthcare professionals a pipeline of high-quality biosimilars in the future"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze